Articles On Recce Pharmaceuticals (ASX:RCE)

Synthetic antibiotics developer Recce Pharmaceuticals has tasked Shaw and Partners with raising fresh funds for the company on Tuesday. 

Shaw and Partners has been appointed as Lead Manager to an equity capital raising by Recce Pharmaceuticals Limited (RCE).   RCE is undertaking a placement of approx. 15.5... Read More

Publicly traded companies lay great emphasis on their respective share price, which mirrors their overall financial health. Analysts, media houses and industry experts vigilantly gauge at the stocks riding high on stock exchanges. Typically...

The company is pioneering the development of a new class of synthetic antibiotics with broad-spectrum activity, designed to address the problem of antibiotic superbugs.

This week only six directors traded $100,000 or more. So we’ve also recapped some big directors’ trades from earlier this year seeing if they paid off – including that millennial director who spent $100,000 on his company rather than a hous...

Pot stock Botanix (ASX:BOT) says one of its cannabis formulations kills superbugs — in animals and in the lab. Botanix is better known to investors as a biotech developing cannabis-based medications for skin conditions, but it also has a re...